Logo

Exelixis Reports the US FDA's Acceptance of IND for XB002 in Patients with Advanced Solid Tumors

Share this

Exelixis Reports the US FDA's Acceptance of IND for XB002 in Patients with Advanced Solid Tumors

Shots:

  • The US FDA has accepted IND to assess the safety- tolerability- PK- and preliminary antitumor activity of XB002 in patients with advanced solid tumors. The P-I trial is expected to initiate in Q2’21
  • The preclinical data demonstrated that XB002 binds to tissue factors without affecting the coagulation cascade- in contrast with prior therapies in this class. The data also showed improved tolerability- tumor growth inhibition and complete regression
  • XB002 (ICON-2) is an ADC composed of a human mAb against tissue factor and have an improved therapeutic index and favorable safety profile compared with earlier-generation tissue factor-targeting ADCs

  Ref: Exelixis | Image: Exelixis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions